| Heading: |
Trastuzumab Deruxtecan |
| Question ID: |
1728650 |
| UIN: |
5192 |
| House: |
Commons |
| Date tabled: |
2024-09-10 |
| Asking Member ID: |
5040 |
| Asking Member display name: |
Liz Jarvis
|
| Asking Member handle: |
lizjarvisuk
|
| Asking Member Twitter reference: |
@lizjarvisuk
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what steps he is taking to review access to the cancer drug Enhertu. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2024-09-18 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE), on the basis of an evaluation of a treatment’s costs and benefits. The NICE’... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |